The original success of Sildenafil undeniably revolutionized the drug landscape, but placing funds in companies strongly reliant on off-patent versions presents a challenging picture. Despite early earnings were significant, the end of patents and the appearance of less expensive alternatives have weakened sales. Consequently, a thorough analysis o